CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
This study has been completed.
Sponsor:
Sanofi
Collaborator:
Bristol-Myers Squibb
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00174759
First received: September 9, 2005
Last updated: January 10, 2011
Last verified: January 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary objective:
To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100 mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in patients receiving a below knee bypass graft for the treatment of PAD.
Secondary objectives:
Comparison, between the two treatment groups, of :
- Primary patency,
- Assisted primary patency,
- Cardiovascular death / myocardial infarction / stroke / any amputation above the ankle.
- Ankle Brachial Pressure Index (ABPI) changes from baseline
| Condition | Intervention | Phase |
|---|---|---|
|
Arterial Occlusive Diseases |
Drug: Clopidogrel |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft. |
Resource links provided by NLM:
Further study details as provided by Sanofi:
Primary Outcome Measures:
- 1st occurrence over the duration of follow-up of : index bypass graft occlusion based on imaging procedure, or graft replacement or endovascular intervention, or amputation above the ankle of the affected limb or death
Secondary Outcome Measures:
- 1st occurrence of any component of following cluster of events : index bypass graft occlusion,any revascularization procedure or amputation. Change in ABPI.
| Estimated Enrollment: | 1460 |
| Study Start Date: | September 2004 |
Eligibility| Ages Eligible for Study: | 40 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria: A patient is eligible for inclusion in the study 2-4 days after surgery if all the following criteria are fulfilled:
- Informed consent obtained;
- Chronic background treatment with daily ASA, whatever the dose, started at least 4 weeks before surgery. A window of a few days without ASA before surgery is acceptable, according to local practice. Post-randomization use of ASA must be between 75 and 100 mg/day.
- Unilateral below knee bypass graft (i.e. the distal anastomosis is below the level of the knee joint) for atherosclerotic PAD within the previous 4 days;
- Demonstration of initial patency of the index graft by an objective measurement (e.g. intra-operative Doppler scanning, flow measurement, angiography, Duplex scanning) during bypass surgery, or between surgery and the time of randomization;
- No clinical evidence of graft occlusion at time of randomization.
Exclusion criteria :
PAD medical/surgical history
- Onset of PAD symptoms before the age of 40 years
- Non-atherosclerotic vascular disease (e.g. Buerger's disease, popliteal entrapment syndrome)
- Patient receiving aorto-bifemoral, iliac-femoral or crossover (femoral-femoral) grafts, or undergoing peripheral transcutaneous angioplasty (PTA), with or without stenting, during the same surgery.
Medical history related to bleeding risk
- Current active bleeding at surgical site
- Withdrawal of an epidural catheter less than 12 hours before randomization
- Current active bleeding or increased risk of bleeding, such as severe hepatic insufficiency, proliferative diabetic retinopathy, peptic ulceration, bleeding diathesis or coagulopathy
- Peptic ulceration within 12 months of randomization
- Previous or current intracranial hemorrhage or hemorrhagic stroke, or any previous stroke for which the diagnosis of hemorrhagic stroke cannot be excluded
- Any history of severe spontaneous bleeding such as gastrointestinal bleeding, gross hematuria, intraocular bleeding
Other medical conditions
- Previous disabling stroke (severe cerebral deficit such that the patient is bedridden or demented)
- NYHA Class IV heart failure
- Uncontrolled hypertension: Systolic Blood Pressure (SBP) > 180 mm Hg, or Diastolic Blood Pressure (DBP) > 100 mm Hg
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00174759
Locations
| Australia | |
| Sanofi-Aventis | |
| North Ryde, Australia | |
| Austria | |
| Sanofi-Aventis | |
| Vienna, Austria | |
| Belgium | |
| Sanofi-Aventis | |
| Brussels, Belgium | |
| Finland | |
| Sanofi-Aventis | |
| Helsinki, Finland | |
| France | |
| Sanofi-Aventis | |
| Paris, France | |
| Germany | |
| Sanofi-Aventis | |
| Berlin, Germany | |
| Hungary | |
| Sanofi-Aventis | |
| Budapest, Hungary | |
| Italy | |
| Sanofi-Aventis | |
| Milan, Italy | |
| Netherlands | |
| Sanofi-Aventis | |
| Gouda, Netherlands | |
| Poland | |
| Sanofi-Aventis | |
| Warsaw, Poland | |
| Spain | |
| Sanofi-Aventis | |
| Barcelona, Spain | |
| Sweden | |
| Sanofi-Aventis | |
| Stockholm, Sweden | |
| Switzerland | |
| Sanofi-Aventis | |
| Meyrin, Switzerland | |
| United Kingdom | |
| Sanofi-Aventis | |
| Guildford, United Kingdom | |
Sponsors and Collaborators
Sanofi
Bristol-Myers Squibb
Investigators
| Study Director: | Luc Sagnard | Sanofi |
More Information
No publications provided by Sanofi
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00174759 History of Changes |
| Other Study ID Numbers: | C_9253, EudraCT #: 2004-000822-58 |
| Study First Received: | September 9, 2005 |
| Last Updated: | January 10, 2011 |
| Health Authority: | Scotland: Scottish Executive Health Department |
Additional relevant MeSH terms:
|
Arterial Occlusive Diseases Peripheral Arterial Disease Peripheral Vascular Diseases Vascular Diseases Cardiovascular Diseases Atherosclerosis Arteriosclerosis Aspirin Clopidogrel Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Central Nervous System Agents Purinergic P2Y Receptor Antagonists |
ClinicalTrials.gov processed this record on May 19, 2013